-

11:58:59 AM

XAIR Stock News

XAIR - Beyond Air Inc

05/17/22 4:05 PM

Nasdaq : XAIR

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

A total of 2,323 inhalations have been self-administered at home to date with no treatment related discontinuations reported and overall high treatment compliance All subjects have successfully titrated to receive the target 250 ppm NO regimen at home LungFit® GO is the first NO generator and

RHEA-AI

neutral

05/17/22 7:00 AM

Nasdaq : XAIR

management

Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the

RHEA-AI

neutral

05/16/22 7:05 AM

Nasdaq : XAIR

earnings

Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with

RHEA-AI

neutral

04/25/22 4:05 PM

Nasdaq : XAIR

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

04/25/22 7:00 AM

Nasdaq : XAIR

covid-19

Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022

Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard supportive treatment Duration of oxygen support was significantly shorter for subjects treated

RHEA-AI

neutral

04/18/22 7:00 AM

Nasdaq : XAIR

conferences

Beyond Air® to Participate in Three Upcoming Medical Conferences

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

04/11/22 7:00 AM

Nasdaq : XAIR

clinical trial

Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect

Data suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response Supports the hypothesis for the observed rejection of secondary tumors in gNO-treated

RHEA-AI

neutral

03/08/22 4:35 PM

Nasdaq : XAIR

conferences

Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing

RHEA-AI

neutral

02/10/22 4:05 PM

Nasdaq : XAIR

earnings

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

LungFit ® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer™, Beyond Air maintained an 80% equity ownership;

RHEA-AI

positive

02/08/22 8:00 AM

Nasdaq : XAIR

conferences

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

1 2 3 4 5 6 Next

XAIR Data

IndustryOther Industrial Machinery Manufacturing
Websitewww.ait-pharm.com
CeoSteven Lisi
Security nameBeyond Air Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees23
Tags
- Technology Services
- Packaged Software
- Manufacturing
- Other Industrial Machinery Manufacturing
Address825 E Gate Blvd Ste 320
StateNew York
CityGarden City
Zip11530-2135
CountryUS
Phone15166658200

About Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.